
Axcella Health AXLA
Quarterly report 2023-Q2
added 08-03-2023
Axcella Health Depreciation & Amortization 2011-2025 | AXLA
Annual Depreciation & Amortization Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 412 K | 288 K | 419 K | 662 K | 1.07 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 M | 288 K | 570 K |
Quarterly Depreciation & Amortization Axcella Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 11 K | - | 290 K | 100 K | 77 K | - | 213 K | 132 K | 64 K | - | 343 K | 251 K | 131 K | - | 518 K | 364 K | 203 K | - | 854 K | 627 K | 355 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 854 K | 11 K | 283 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
1.4 M | $ 4.75 | -0.94 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
807 K | $ 3.03 | -0.49 % | $ 234 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 1.17 | - | $ 6.38 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Aptevo Therapeutics
APVO
|
352 K | $ 0.58 | -37.63 % | $ 160 K | ||
|
BioVie
BIVI
|
229 K | $ 1.2 | -5.51 % | $ 1.77 M | ||
|
Athersys
ATHX
|
1.43 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 0.22 | 25.2 % | $ 479 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
28.2 M | $ 26.9 | 0.34 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
172 M | - | 0.49 % | $ 251 B | ||
|
Anika Therapeutics
ANIK
|
6.43 M | $ 9.52 | 0.42 % | $ 140 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
3.87 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
48.4 M | $ 585.83 | -0.9 % | $ 44.4 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.5 | -1.17 % | $ 15.7 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
1.07 M | $ 12.47 | 0.81 % | $ 821 M | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Celldex Therapeutics
CLDX
|
3.18 M | $ 26.24 | -2.2 % | $ 1.69 M | ||
|
Cellectar Biosciences
CLRB
|
192 K | $ 2.56 | -7.25 % | $ 31.3 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
24.9 M | $ 10.82 | 0.14 % | $ 700 M | ||
|
Biogen
BIIB
|
673 M | $ 175.8 | -0.3 % | $ 25.6 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
5.63 M | - | - | $ 7.29 B |